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Summary 
In previous in situ and in vivo rat perfusion studies, the intestinal absorption 
of several low molecular weight drugs was increased by the presence of luminal D- 
glucose. The intent of this study was to determine the potential of this fed-state 
effect to improve the intestinal uptake of poorly permeable, small peptide and 
peptide-like drugs. Jejunal wall permeabilities (Pw*) of di-(D-kyotorphin), tri- 
(cephradine), hexa-(growth hormone releasing peptide, GHRP-6) and octa- 
(octreotide, a somatostatin analogue) peptides and corresponding net water fluxes 
were determined in rats using an in situ single-pass perfusion technique. Glucose 
was shown to enhance the uptake of the smaller (di- and tri-) peptides but not the 
larger peptides despite the fact that glucose elicited a significant net water absorption 
with each of the four peptide drugs. It is concluded that glucose enhances jejunal 
permeabilities of smaller peptides by solvent drag and the enhancement is limited in 
si tu by peptide molecular size. The studies with nonmetabolizable 3-0- 
methylglucose suggest that the augmentation of the proton gradient across the 
transmucosal membrane by glucose contributes to the carrier-mediated transport 
observed with the smaller peptides. 
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The ongoing discovery of endogenous peptides with promising therapeutic potential 
necessitates the development of an efficient and practical mean of medicinal peptide delivery. Since 
indications for peptide drugs typically involve chronic pathology requiting long-term therapy, oral 
delivery is the first-choice route of administration. Unfortunately, the potential for successful oral 
treatment is often undermined by peptide instability towards gastrointestinal proteolytic enzymes 
and low peptide intestinal membrane permeability. These two limitations couple with hepatic 
clearance to restrict the extent of systemic delivery of an orally dosed peptide drug. To mitigate the 
stability problem, synthetic peptidic drugs such as octreotide (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys- 
Throl), a somatostatin analogue, for treatment of neuroendocrine tumors (1), and growth hormone 
releasing peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; GHRP-6) for pituitary dwarfism (2) have 
been developed with substantial resistance to proteolytic enzymes. This has been accomplished 
through cyclization (octreotide) and replacement of L-amino acids with D-amino acids (octreotide 
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and GHRP-6). Although the dramatically improved stability maximizes the luminal driving force 
for intestinal absorption, poor lipophilicity and/or significant aqueous hydrogen binding potential 
restrict intestinal membrane permeation (3). Furthermore, large molecular size (octreotide, 
octapeptide; GHRP-6, hexapeptide) precludes peptide uptake by the intestinal peptide carrier system 
(4,5). 
For oral administration of oligopeptides to result in therapeutic success, absorption- 
enhancing agents may provide an avenue to promote intestinal solute uptake. While some of these 
agents produce transient histological damage (6), a consideration of fed-state influences on intestinal 
absorption offers a class of permeability enhancing agents for which toxicity and safety concerns 
are minimal. Nutrients, such as D-glucose and amino acids, have been shown to enhance solute 
membrane permeability by induction of both solvent drag and structural alterations of tight junctions 
gating the paracellular pathway (7-11). An I 1-amino acid hemepeptide (m.w. 1900) has been 
reported to permeate intestinal tight junctions in connection with glucose-elicited junctional dilation 
in vi tro (12). The therapeutic potential of these findings has prompted an investigation into the 
nutrient-enhanced intestinal transport of relatively stable peptide drugs. 
In this report, the effect of glucose on rat jejunal absorption of peptides was examined using 
an in s i tu  single-pass perfusion technique. Large peptides, namely, GHRP-6 and octreotide, were 
chosen as candidates based on their relative stability to enzymatic degradation. D-kyotorphin and 
cephradine were also selected to determine the possible effect of glucose on the proton-gradient- 
driven intestinal absorption of a dipeptide drug and a tripeptide-like 13-1actam antibiotic (4,13) since 
the luminal presence of glucose augments the acidity of the microclimate layer in the small intestine 
(14-17). These smaller candidates are enzymatically stable and potential substrates for the proton 
gradient-driven mucosal peptide carrier. These four peptides should provide an adequate test of the 
glucose potential to enhance the small intestinal absorption of peptides as a function of peptide 
molecular size (Table I). The relative influences of glucose-induced solvent drag and glucose- 
enhanced transmucosal proton gradient on peptide transport were studied utilizing nonmetabolizable 
3-O-methylglucose (3OMG) which does not alter the microclimate pH (14,17) but does stimulate 
water absorption to generate solvent drag (18). In addition, peptide stability against brush-border 
membrane enzymes and luminal enzymes was verified in vitro. 
TABLE I 
Structure and Molecular Weight of The Peptides Studied 
Peptide St ruc tu  re Mol. Weight 
Octreotide (D-Phe)-Cys-Phe-(D-Trp)-Lys-Cys-Throl 1 0 2 0 
GHRP-6 His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH 2 8 7 3 
Cephradine Tripeptide-like 349 
D-Kyotorphin Tyr-(D-Arg) 337 
Materials and Methods 
GHRP-6 (SK&F 110679) was provided by SmithKline Beecham Pharmaceuticals (King of 
Prussia, PA). Sandostatin (Octreotide Acetate for Injection, Sandoz Inc., East Hanover, N J) was 
obtained from the University of Michigan Hospital Pharmacy. D-kyotorphin, cephradine, D- 
glucose, 3-O-methylglucose, D-mannitol, ethanesulfonic acid (Mes), N-[2-hydroxyethyl] 
piperazine-N'-[2-ethanesulfonic acid] (Hepes), [hydroxymethyl] aminomethane (Tris) and 
polyethylene glycol (PEG) 4000 were purchased from Sigma Chemical Co. (St. Louis, MO). 14C- 
PEG 4000 was obtained from New England Nuclear (Boston, MA). All other chemicals were of 
reagent grade. 
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Stability of Peptides in Intestinal Brush-border Membranes 
Intestinal brush-border membrane vesicles (BBMV) were prepared from rabbit small 
intestine according to the calcium precipitation method (19). The extent of purification of the brush- 
border membrane fraction was assessed by measuring alkaline phosphatase activity. The specific 
activity of this brush-border enzyme was enriched 18-fold in the final preparation. The final BBMV 
preparation was suspended in 10 mM Hepes/Tris buffer (pH 7.0) containing 100 mM mannitol and 
100 mM KC1 and stored at -80 °C until use. Stability of peptides was studied by incubating 20 gL 
of BBMV suspension (containing 25 gg protein) with 80 lxL of peptide solution (100 IxM GHRP-6, 
5 ktM octreotide, 25 ktM D-kyotorphin, each in 10 mM Mes buffer) at pH 6.5 at 37 °C. At selected 
times, reaction was terminated by addition of 10 IxL of 10% trifluroacetic acid (TFA) solution. 
After centrifugation at 5000 rpm (Microfuge E, Beckham Instruments, Palo Alto, CA), the 
supernatant was analyzed by HPLC. 
Stability of Peptides in Luminal Contents 
Luminal solution was obtained from single-pass perfusion of rat jejunum in situ. Exiting 
perfusate was collected from single-pass perfusion of 10 cm of jejunum with iso-osmotic Mes 
buffer (pH 6.5) carried out at 0.75 mL/min over 20 minutes using a Harvard perfusion pump 
(Harvard Apparatus, South Natick, MA). Stability of peptides was tested by mixing 9.5 mL blank 
perfusate with 0.5 mL of each peptide solution (100 I.tM GHRP-6, 5 ktM octreotide, 25 I.tM D- 
kyotorphin) and incubating the mixture at 37 °C. At selected times, 0.45 mL aliquot was mixed 
with 0.05 mL of 10% TFA solution and centrifuged at 5000 rpm; the supernatant was then assayed 
by HPLC. 
In Situ Single-Pass Jejunal Perfusion 
The in situ single-pass jejunal perfusion method was used without modification for 
octreotide, GHRP-6, D-kyotorphin and cephradine as previously described (20). Briefly, male 
Sprague Dawley white rats (weighing 300-350 g) were fasted overnight with free access to water. 
Following anesthesia with 4.5 g/Kg body weight of urethane, the abdomen was opened by a 
midline longitudinal incision and a 10 cm jejunal segment (beginning 5 cm distal to the ligament of 
Trietz) was cannulated. Peptide solutions (100 gM GHRP-6, 5 gM octreotide, 25 gM D- 
kyotorphin and 2 mM cephradine) were perfused at 0.2 mL/min through the segment and output 
perfusate was collected every 10-minute interval for 90 minutes. Coperfusions of peptides with 
glucose and 3OMG were compared to that with mannitol (control). All perfusion solutions 
contained carbon 14-traced (specific activity 0.12 l.tCi/p.mol) 0.01% PEG 4000 as a nonabsorbable 
marker. Perfusion solutions were made iso-osmotic with sodium chloride and buffered at pH 6.5 
with 10 mM Mes solution. 
Dimensionless wall permeabilities (Pw*) were calculated from peptide input-to-output 
perfusate concentration ratios corrected for water volume change averaged over the last five 10- 
minute (steady-state) collection samples according to the previously published model (20). Net 
water fluxes normalized by the length of the perfused segment (t.tL/min-cm) were determined by 
change in the concentration of PEG 4000 (10). It should be noted that in this paper, positive values 
of net water flux indicate net water absorption and negative values net water secretion. 
Analytical Methods 
Jejunal net water flux was determined by measurement of 14C-PEG 4000. Half milliliter 
perfusate samples were mixed with 10 mL scintillation cocktail (EcoLite (+), ICN Chemical Inc., 
Costa Mesa, CA) and counted on a Beckman LS 9000 scintillation counter (Beckman Instruments 
Inc., Fullerton, CA). 
Peptide concentrations in the perfusate and the vesicle samples were determined by high 
performance liquid chromatography methods. The instrumentation consisted of an auto injector 
(Waters, WISP Model 710B, Milford, MA), an absorbance detector (Kratos, Spectroflow Model 
773, Ramsey, NJ) and a reverse-phase column (Lichrosorb RP-18, 10um, F.R. Germany). For 
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GHRP-6, the mobile phase (30% acetonitrile in 100 mM ammonium phosphate-5 mM sodium 
hexanesulfonate-0.28% triethylamine buffer, pH 4) flow was set at 1.5 mL/min and eluent 
monitored at 210 nm. For octreotide, the mobile phase (40% acetonitrile in 10 mM ammonium 
acetate buffer, pH 4) flow was set at 1.4 mL/min and eluent monitored at 210 nm. For D- 
kyotorphin, the mobile phase (6% acetonitrile in 10 mM ammonium acetate, pH 4) flow was set at 
1.4 mL/min and eluent monitored at 274 nm. For cephradine, the mobile phase (13% acetonitrile in 
20 mM sodium phosphate buffer, pH 5) was set at 1.7 mL/min and eluent monitored 262 nm. 
Results 
Stability of D-kyotorphin, GHRP-6 and octreotide in the jejunal perfusate (luminal 
enzymes) and the BBMV (mucosal membrane enzymes) are illustrated in Fig. 1. All three peptides 
tested were shown to remain more than 80% intact over an incubation period of at least one hour in 
the jejunal perfusate while their stability in the BBMV was relatively high and ranked at the order 
octreotide>GHRP-6>D-kyotorphin with half lives of 433, 200 and 107 minutes, respectively. D- 
kyotorphin was the least stable, but it was significantly more stable than L-kyotorphin (half life < 5 
minutes; data not shown). Cephradine has been previously demonstrated to be stable in the jejunal 
perfusate with a half life of about 100 minutes (21) while its stability in the BBMV was also 
adequate over the time course of the studies (22). 
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Stability of peptides in the rat jejunal perfusate and the rabbit BBMV. The initial 
peptide concentrations in the perfusate and in the BBMV were 0.25 and 4 l.tM for 
octreotide; 5 and 80 ~tM for GHRP-6; 1.25 and 20 IxM for D-kyotorphin; 
respectively. 
In rat jejunal perfusion experiments, steady-state dimensionless membrane permeabilities 
(Pw*) were obtained after 30 minutes of perfusion and reported as the mean value from 40-80 
minutes of perfusion. Permeabilities were determined in the presence of 112 mM luminal glucose 
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or 3OMG versus D-mannitol as a control. Net water fluxes (as BL/min per cm of perfused 
intestinal length) were also measured and reported as positive values for net water absorption and 
negative values for net water secretion. 
The influence of the coperfusion of 112 mM glucose on the jejunal permeabilities of 
octreotide, GHRP-6, D-kyotorphin and cephradine and the net water fluxes at pH 6.5 is shown in 
Fig. 2. Compared to mannitol (control), glucose induced a significant net water absorption with 
each of the four peptides (lower panel). However, only the permeabilities of the smaller peptides, 
D-kyotorphin and cephradine, were significantly enhanced. It is noteworthy that glucose generated 
significantly less water absorption in the presence of luminal octreotide than in the absence of 
octreotide (p<0.01; Student's t-test). 
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Fig. 2 
Influence of the coperfusion of 112 mM glucose on the jejunal dimensionless wall 
permeabilities (Pw*) of the peptides (upper panel) and the net water fluxes (lower 
panel) at pH 6.5. Mannitol was used as control. The concentrations of octreotide, 
GHRP-6, D-kyotorphin and cephradine were 5 lxM, 100 }xM, 25 I.tM and 2 mM, 
respectively. Results are expressed as the mean + standard error of three rats. * 
Statistically significant difference (p < 0.05) based on Student's t-test as compared 
with each mannitol control. 
The effect of glucose on the jejunal permeabilities of D-kyotorphin and cephradine was 
further compared to that of 3OMG which, unlike glucose, is nonmetabolizable inside the luminal 
ceils and the results are presented in Table II. The permeabilities of D-kyotorphin and cephradine at 
pH 6.5 were significantly increased to the same extent with 3OMG as with glucose. This is 
consistent with increased net water absorption generated by either monosaccharide for both D- 
kyotorphin and cephradine. 
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The effect of  glucose (versus 3OMG) on cephradine permeabil i ty  and net water  flux 
depends on the perfusate pH (Table III). The results indicate that the enhancement of  cephradine 
permeabil i ty at pH 7.5 by 3OMG (Pw* from 2.3 to 2.5) was less than that at pH 6.5 (Pw* from 
2.3 to 4.0) whereas this pH-dependence was not observed with glucose coperfusion. It was also 
found that there was a lack of  pH-dependence of  monosaccharide-generated net water absorption 
for both glucose and 3OMG. 
TABLE 11 
Comparison of  glucose (metabolizable) versus 3OMG (nonmetabolizable)  with 
regard to their influence on the jejunal dimensionless wall permeabilities (Pw*) of  D- 
kyotorphin (25 ~tM) and cephradine (2 mM), and the net water fluxes at pH 6.5. 
Dimensionless Wall Permeability Net Water Flux 
Pepfide (Pw*) (p.ldmin-cm) 
Perfused Mannitol a Glucose 3OMG Mannitol Glucose 3OMG 
D-Kyotorphin 0.059 ± 0.617 ± 0.393 ± -0.439 ± 2.456 + 1.885 + 
0.035 b 0.102"* 0.065** 0.147 0.375** 0.313"* 
Cephradine 2.318 ± 3.914 ± 3.980 + 0.085 ± 3.243 ± 2.300 ± 
0.406 0.603** 0.273** 0.269 0.443** 0.195"* 
a Concentration of  the coperfused monosaccharides was 112 mM. 
b Results are expressed as the mean + standard error of  three rats. 
**Statistically significant difference based on Student's t test (p < 0.05) as compared 
with each control (mannitol). 
TABLE HI 
Effect of  the perfusate pH on the jejunal dimensionless wall permeabili ty (Pw*) of  
cephradine (2 mM) and the net water flux. 
Dimensionless Wall Permeability Net Water Flux 
Monosaccharide (Pw*) (pJ_,/min-cm) 
Coperfused a pH 6.5 pH 7.5 pH 6.5 pH 7.5 
Glucose 3.914 ± 3.409 ± 3.243 ± 3.040 ± 
0.603 b 0.697 0.443 0.339 
3OMG 3.980 + 2.486 + 2.300 + 2.230 + 
0.273 0.440** 0.195 0.162 
a Concentration of  the coperfused monosaccharides was 112 raM. 
b Results are expressed as the mean + standard error of  three rats. 
**Statistically significant difference between pH 6.5 and pH 7.5 (p < 0.05) based 
on Student's t-test. 
Discussion 
In previous in situ (9,10) and in vivo (1 1) studies, glucose was shown to increase the 
jejunal permeability of  low molecular weight drugs (m.w. 150-350). This fed-state effect is of  little 
in vivo consequence for lipophilic drugs whose absorption is dissolution-rate controlled; however, 
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the systemic availability of small hydrophilic drugs may be improved when the oral absorption is 
limited by low membrane permeability. While small peptide drugs are in this latter physicochemical 
class, metabolism by gastrointestinal (GI) enzymes may further limit absorption potential. 
Fortunately, recent drug discovery efforts have produced peptide drugs that are significantly smaller 
(4-8 amino acids) yet relatively more stable to GI degradation than the endogenous parent peptides. 
In an in vitro study, glucose-enhanced intestinal permeation of an undecapeptide (m.w. 
1900) has been associated with a dilation of the tight junctions (12). The more recent in situ (9,10) 
and in vivo (11) studies has further suggested the involvement of convective intestinal water flow 
(solvent drag) in glucose-enhanced uptake of small drug molecules. Therefore, this undertaken 
investigation was aimed to determine if luminal glucose would increase the intestinal absorption of 
stable peptide drugs in situ. Since the previous studies have indicated that glucose increases 
intestinal absorption of small solutes by solvent drag through dilated paracellular pathways, the 
dependence of this effect on molecular size was also investigated. The selection of stable peptide 
drug candidates included a dipeptide and a tripeptide-like B-lactam antibiotic which are potential 
substrates for the mucosal peptide carrier. The transport of small peptides by this carrier system is 
driven by a transmucosal proton gradient (4,13); cellular glucose metabolism serves to enhance this 
gradient providing an additional glucose effect. In order to separate glucose-stimulated solvent drag 
from proton gradient effects, the influence of luminal pH and 3OMG, a nonmetabolizable and 
actively transported monosaccharide, on peptide transport was studied. 
The stability studies on all four peptide drugs indicated that they were relatively stable in the 
jejunum (Fig. 1). Although there was a significant degree of degradation for D-kyotorphin in 
brush-border membrane vesicles, its stability was sufficient to allow an accurate estimation of 
jejunal permeability since the residence time of the peptide in the jejunal lumen in perfusion 
experiments was relatively short (about 6 min) compared to its half life (107 min) so that a 
negligible amount of peptide underwent degradation. 
The jejunal perfusion studies showed that the permeabilities of both cephradine and D- 
kyotorphin (m.w. about 350) were significantly increased by luminal glucose while this was not the 
case for octreotide or GHRP-6 (m.w. > 850) (Fig. 2). The corresponding increases in net water 
absorption by glucose suggest that the enhanced permeabilities of the small peptides result from the 
solvent drag effect (Fig. 2). One plausible hypothesis for the lack of glucose effect on the 
permeabilities of the large peptides is that sodium/glucose co-transport produces a dilation of the 
tight junction only large enough to admit the small peptides. 
Baseline permeability of the dipeptide D-kyotorphin was surprisingly low (Fig. 2). It is 
possible that the N-terminal D-arginine renders D-kyotorphin a poor dipeptide substrate for the 
mucosal peptide carrier (23-25). In addition, the low D-kyotorphin control permeability is 
consistent with paracellular uptake diminished by luminal D-kyotorphin generated water secretion 
(Fig. 2). The baseline permeability of the tripeptide-like cephradine was quite high under these 
perfusion conditions (Fig. 2) indicating that a substantial transport contribution is mediated by the 
mucosal peptide carrier. 
The net water absorption generated by glucose was equivalent to 3 IxL/min-cm for each of 
the p.eptides except octreotide (1 IxL/min-cm) (Fig. 2). The larger net water flux is equivalent to 
previous data obtained in rat jejunal perfusions of glucose both in situ (9,10) and in vivo (11). 
The reduction in glucose-induced water absorption with octreotide perfusion is consistent with 
octreotide's capacity to diminish upper intestinal glucose absorption (26). 
Glucose enhanced the permeability of both cephradine and D-kyotorphin, but a different 
extent of enhancement was observed (1.6 for cephradine and 0.56 for D-kyotorphin) (Table II). If 
the increase in permeability only represented glucose-stimulated solvent drag of the smaller peptides 
through paracellular pathways, a similar increase in dimensionless wall permeability would have 
been expected for both cephradine and D-kyotorphin considering their equivalent molecular size. 
Therefore, an investigation of the potential contribution of cellular glucose metabolism to favorably 
influence small peptide transport by enhancing the inwardly directed transmucosal proton gradient 
was carried out. The effect of enhanced transmucosal proton gradient can be separated from the 
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solvent drag effect by utilizing nonmetabolizable 3OMG. 3OMG is a substrate for the mucosal 
sodium/glucose cotransporter as well as the basolateral sodium-independent glucose carrier (27) and 
is capable of promoting net water absorption following transepithelial sodium movement similar to 
glucose (Table III). However, 3OMG will not lower microclimate pH through mucosal 
sodium/proton exchange as is observed subsequent to cellular glucose metabolism (14). From the 
studies, it was found that cephradine permeability from coperfusion with 3OMG at pH 7.5 was 
significantly lower than that at pH 6.5 while the permeability from coperfusion with glucose was 
not affected by the perfusate pH (Table III). This observation, which is not the result of solvent 
drag since net water absorption was not pH-dependent for either monosaccharide (Table III), may 
be explained by the metabolizable glucose's capacity of maintaining a high proton gradient for 
carrier-mediated cephradine transport at higher luminal pH (7.5). The cephradine permeability 
results suggest that metabolic depression of microclimate pH contributes to the overall glucose 
effect on small intestinal peptide absorption. 
In summary, poorly absorbed stable di-and tri-peptides are candidates for glucose-enhanced 
small intestinal absorption. The enhanced absorption of these small peptides appears to result from 
the glucose-elicited solvent drag effect and the microclimate pH effect. The small molecular size of 
the di- and tri-peptides provides a reflection coefficient less than one indicative of paracellular 
transport. The water absorption generated by sodium co-transported monosaccharides mediates 
convective drag of solute past expanded tight junctions (12). In addition, since the absorption of 
some di- and tri-peptides is mediated by the proton-coupled peptide carrier, glucose-generated 
lowering of microclimate pH elevates the mucosal proton gradient thus increasing the driving force 
for carrier-mediated transport. The solvent-drag effect and the microclimate pH effect should be of 
utility for enhancing the absorption of small peptides that are poor substrates for the small-intestinal 
peptide carrier. Small peptides, chemically modified for stability, and low molecular weight 
peptidomimetic solutes would fall into this class of solutes. However, these studies also suggest 
that there is not a significant potential for glucose enhancement of absorption of stable peptide drugs 
as large as hexapeptides. Peptides of this size are not substrates for the carrier and are sufficiently 
large to be totally reflected by paracellular size restriction. These latter results define the limitations 
of this fed-state effect for enhancing the absorption of small peptide drugs. 
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